The DOI matches its Crossref record.
Radiolabeled Tracers for Imaging of Tumor Angiogenesis and Evaluation of Anti-Angiogenic Therapies
Abstract
A variety of therapeutic strategies in oncology are focused on the inhibition of tumor-induced angiogenesis. Thus, there is a keen interest in methods which allow non-invasive monitoring of molecular targets involved in angiogenesis which would support information for planning and controlling corresponding therapies. Moreover, such techniques would provide an insight into the formation of new sprouting blood vessels, the involved processes and regulatory mechanisms in patients. At the moment, development of radiotracer based techniques is mainly concentrated on three different targets which include peptidic and non-peptidic alpha v beta 3-integrin binding antagonists, matrix metalloproteinase inhibitors and single chain anti-fibronectin antibody fragments. Development of radiolabeled MMP inhibitors is based on either the decapeptide Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys resulting from a phage display library or small molecular weight compounds. The in vitro data for these tracers are very promising. However, more detailed in vivo data are necessary to evaluate the potency of MMP-inhibitors for in-vivo imaging. The radiolabelled anti-ED-B single chain antibody fragment scFv L-19 shows selective accumulation in the tumor vasculature in a murine tumour model. In a first patient study a selective localisation of the (123)I-labeled tracer in lesions of different tumours was found. On the basis of the lead structure cyclo(-Arg-Gly-Asp-dPhe-Val) a variety of different radiolabeled RGD-peptides has been developed for the non-invasive determination of the alpha v beta 3 expression. These developments include peptides labeled with minimum structural alteration, peptide carbohydrate conjugates, peptidomimetics based on the RGD-structure as well as heterodimeric, homodimeric and homotetrameric ligand systems. Many of the tracers show high alpha v beta 3-affinity and selectivity in vitro and receptor selective tumour accumulation with high image contrast in different murine tumour models. Further studies have to demonstrate that this approach can be translated to clinical settings allowing visualisation of alpha v beta 3-positive tumours and alpha v beta 3 expression during tumour-induced angiogenesis in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Spinale, F. G. (2007) · Physiological Reviews · doi:10.1152/physrev.00012.2007 · Cited by 1,120
Haubner, R., Weber, W. A., Beer, A. J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.-F., Goebel, M., Hein, R., Wester, H.-J., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020070 · Cited by 489
Self-citationNew approaches for imaging tumour responses to treatment
Brindle, K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2289 · Cited by 460
Liu, S. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900167c · Cited by 344
Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3Targeted Radiotracers for Tumor Imaging
Liu, S. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060049x · Cited by 340
Metadata
- Authors
- Haubner, R., & Wester, H.-J.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-05-01
- Volume
- 10
- Issue
- 13
- Pages
- 1439-1455
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2068812502
- Cited by
- 198
- References
- 0
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiolabeled Tracers for Imaging of Tumor Angiogenesis and Evaluation of Anti-Angiogenic Therapies. https://app.cochat.ai/papers/10.2174/1381612043384745
- The paper
- Haubner, R., & Wester, H.-J. (2004). Radiolabeled Tracers for Imaging of Tumor Angiogenesis and Evaluation of Anti-Angiogenic Therapies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612043384745
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.